

# MERGER ANNOUNCEMENT M/25/075 – ASPIRE PHARMA/CARAGEN

## Section 21 of the Competition Act 2002

**Competition and Consumer Protection Commission clears proposed acquisition whereby Aspire Pharma Limited would acquire sole control of Caragen Limited.**

**28 November 2025**

---

The Competition and Consumer Protection Commission has today cleared the proposed transaction whereby Aspire Pharma Limited, via Aspire Topco Limited, which is ultimately controlled by funds managed by H.I.G. Capital LLC would acquire sole control of Caragen Limited. The proposed transaction was notified under the Competition Act 2002, as amended, on 11 November 2025.

The Commission has formed the view that the proposed transaction will not substantially lessen competition in any market for goods or services in the State. The Commission will publish the reasons for its determination on its website no later than 60 working days after the date of the determination and after allowing the parties the opportunity to request that confidential information be removed from the published version.

### **Additional Information**

Aspire Pharma Limited develops, licenses and sells a range of pharmaceutical products. Aspire Pharma Limited is incorporated in England and Wales. Aspire Pharma Limited is ultimately controlled by H.I.G. Capital LLC.

H.I.G. Capital LLC is a global private equity and alternative assets investment firm specialising in providing both debt and equity capital to small and mid-sized companies. H.I.G. Capital is incorporated in the State of Delaware, USA.

Caragen Limited sources, sells, markets and distributes pharmaceutical products and medical devices. Caragen Limited is incorporated in Ireland.